Skip to main content

Radiation Oncology Perspective

The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer



A Frontline Forum hosted by CancerNetwork during the 2025 American College of Radiation Oncology Summit in March focused on gene expression testing options for patients with prostate cancer.

The discussion centered on genetic vs genomic testing, current NCCN guidelines, and decisions based on which testing options to use. Following the program, CancerNetwork spoke with leading clinicians in the radiation oncology space regarding the use of these tests, androgen deprivation therapy (ADT), and the thought process for selecting patients for active surveillance.

To begin, the distinction between a genomic biomarker vs germline testing was mentioned. A genomic biomarker includes a measurable DNA or RNA characteristic that can be used to indicate normal biological processes, disease, or response to treatment. Germline testing is the analysis of DNA to identify genetic variations that may be associated with health risks or cancer predisposition.

Decipher Prostate has a level 1B evidence rating among the NCCN guidelines. A news release from the developer stated that Decipher received the rating because of evidence from the postbiopsy and postprostatectomy settings.

Decipher Prostate is a 22-gene test incorporating RNA whole-transcriptome analysis plus machine learning to help inform treatment decisions for patients with prostate cancer. Biopsy or surgically resected samples are used to provide a patient’s risk for developing metastases with standard treatment. This information will better personalize care as well as provide options that are less treatment-intensive. Validation for this test comes from more than 75 studies and more than 100,000 patients.

The Oncotype DX test is a 17-gene assay that was created to assess 12 cancer-related genes and 5 reference genes through biopsy tissue.

A recent study looking into genomic classifiers across 10 studies reported the risk reclassification. In studies that had a low risk of bias and patients with prostate cancer who were very low or low risk, patients were more likely to have their risk levels classified as the same or lower with Oncotype DX at 100% to 88.1%, Decipher at 87.2% to 82.9%, and Prolaris at 76.9%. There was, however, 1 randomized trial of genomic classifiers with Oncotype DX that reclassified 34.5% of patients who were very low risk and 29.4% who were low risk to the high-risk category.

The study takeaway mentioned a need for more trials to better determine the role of genomic classifiers for patients with newly diagnosed prostate cancer who are considering first-line treatment.

The NCCN guidelines include Prolaris in the prostate cancer guidelines with category level 2A of evidence. This is a molecular diagnostic test that can provide personalized information regarding the aggressiveness of a tumor and can determine whether a patient should pursue treatment. Of note, a news release from Myriad Genetics stated that it is the only biomarker test to quantify the benefits of ADT to radiation therapy.

Findings from a study by Tward et al found the combined clinical cell-cycle risk (CCR) score for a single therapy that is a continuous variable was able to prognosticate metastases (HR, 3.97; 95% CI, 2.61-6.06) as well as for the dichotomized threshold (HR, 15.90; 95% CI, 5.43-46.52).5 If patients were given single-modality therapy of radiation therapy or surgery, the 10-year Kaplan Meier score was 4.3% (95% CI, 1.0%-17.1%) for those with a CCR score below the threshold and 20.4% (95% CI, 13.2%-30.7%) for those with a score above the threshold.

The authors stated that if the CCR score was below the 2.112 multimodality threshold, patients could safely avoid multimodality therapy. Additionally, clinicians can use the CCR scores to counsel patients on which type of therapy would be most effective for intermediate or high-risk prostate cancer.

A discussion during the program also occurred around clinical decision-making. The program also focused on active surveillance, which is used to identify appropriate candidates who are eligible for this treatment with favorable or intermediate disease; treatment modality selection included guiding choices between single and multimodality approaches; and ADT optimization was determining if there was a benefit by adding ADT to radiation therapy.

breast cancer, lung cancer, prostate cancer, colorectal cancer, pancreatic cancer, leukemia, lymphoma, melanoma, ovarian cancer, cervical cancer, esophageal cancer, kidney cancer, liver cancer, thyroid cancer, bladder cancer, bone cancer, stomach cancer, multiple myeloma, brain tumor, and skin cancer

#BreastCancer, #LungCancer, #ProstateCancer, #ColorectalCancer, #PancreaticCancer, #Leukemia, #Lymphoma, #Melanoma, #OvarianCancer, #CervicalCancer, #EsophagealCancer, #KidneyCancer, #LiverCancer, #ThyroidCancer, #BladderCancer, #BoneCancer, #StomachCancer, #MultipleMyeloma, #BrainTumor, #SkinCancer

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Popular posts from this blog

Chromosomal Abnormalities

  Chromosomal Abnormalities Chromosome abnormalities refer to structural or numerical changes in chromosomes that can disrupt normal genetic function, leading to developmental disorders, congenital abnormalities, and various genetic diseases. These abnormalities may arise from errors in cell division, such as nondisjunction or chromosomal breakage, resulting in conditions like Down syndrome , Turner syndrome, Klinefelter syndrome , and various deletion or duplication syndromes. Understanding chromosome abnormalities is essential for genetic counseling, prenatal diagnosis, disease risk assessment, and research in cytogenetics and molecular genetics. Chromosome abnormalities, chromosomal disorders, chromosomal mutations, aneuploidy, structural chromosome abnormalities, nondisjunction, deletion syndrome, duplication syndrome , translocation, inversion, cytogenetics, karyotyping, prenatal diagnosis , genetic testing, genomic instability, Down syndrome, Turner syndrome, Klinefelter syn...

Human Brain Organoids

Human Brain Organoids Model Abnormal Prenatal Neural Development Induced by Thermal Stimulation The developing human foetal brain is sensitive to thermal stimulation during pregnancy. However, the mechanisms by which heat exposure affects human foetal brain development remain unclear, largely due to the lack of appropriate research models for studying thermal stimulation. To address this, we have developed a periodic heating model based on brain organoids derived from human pluripotent stem cells. The model recapitulated neurodevelopmental disruptions under prenatal heat exposure at the early stages, providing a paradigm for studying the altered neurodevelopment under environmental stimulation. Our study found that periodic heat exposure led to decreased size and impaired neural tube development in the brain organoids. Bulk RNA-seq analysis revealed that the abnormal WNT signalling pathway and the reduction of G2/M progenitor cells might be involved in heat stimulation. Further investi...

Multifactorial Genetic Conditions

Multifactorial Genetic Conditions Multifactorial genetic conditions are disorders caused by the combined effects of multiple genes and environmental factors , rather than a single gene mutation . These conditions do not follow classic Mendelian inheritance patterns and instead result from complex gene–environment interactions . Factors such as lifestyle, nutrition, infections, stress, and exposure to toxins can significantly influence disease onset and severity in genetically susceptible individuals. Common examples include diabetes, cardiovascular diseases , neural tube defects, asthma, and many neuropsychiatric disorders. Understanding multifactorial inheritance is essential for risk prediction, preventive medicine, and personalized healthcare strategies. Multifactorial inheritance, polygenic traits, gene–environment interaction, complex diseases, genetic susceptibility, environmental risk factors, non-Mendelian inheritance, disease predisposition, polygenic risk score, precision ...